에 대한 최신 뉴스 GSK (NYSE:GSK) 주식

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GlaxoSmithKline

Short Ideas

Health Care

Hedge Funds

Trading Ideas

General

iShares Dow Jones US Pharmaceuticals Index Fund

켄 그리핀의 헤지펀드 시타델(Citadel)이 GSK PLC(NYSE:GSK)에 3억 5,000만 파운드(3억 9,000만 달러)의 공매도 베팅을 걸었다. 이는 영국 제약 대기업 GSK에 대한 10년래 가장 큰 베팅이라고 파이낸셜타임스가 보도했다.

켄 그리핀의 헤지펀드 시타델, 제약사 GSK에 대규모 공매도 베팅

Large Cap

News

CVAC

MRNA

NVAX

네바다의 한 낙농업자가 1월에 루이지애나 남자의 사망과 관련된 조류 독감 D1.1 변종에 양성 반응을 보였다고 CNN이 보도했다. 미국 질병통제예방센터(CDC)는 월요일에 초기 양성 반응을 확인하기 위해 작업 중이다.

네바다 남성에서 발견된 치명적인 조류 독감 변종: 주목해야 할 4가지 주식

Equities

Markets

IDNA

미국 질병통제예방센터(CDC)가 세계보건기구(WHO)와의 협력을 중단한 것으로 알려지면서 전 세계 보건 우려가 월요일 높아지는 가운데, 캘리포니아에서 희귀한 H5N9 조류 독감 변종이 발견되어 백신 회의론자 로버트 F. 케네디 주니어에 대한 상원 인준 청문회가 예정된 것과 동시에 이루어졌다.

CDC-WHO 협력 중단 및 조류 독감으로 모더나, 화이자 상승; RFK Jr. 후보 인준 청문회 예정

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

GSK PLC

Precidian ETFs Trust GSK plc ADRhedged

Goldseek Resources Inc Ordinary Shares

Biotech

The China National Medical Products Administration Has Accepted For Review GSK's New Drug Application For Nucala (Mepolizumab) As An Add-on Maintenance Treatment For Patients With Chronic Obstructive Pulmonary Disease With An Eosinophilic Phenotype

Editor&#8217;s Note: The story has been updated to correct the FDA approval date to Friday, February 14
On Friday, February 14, the FDA approved GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25. 
The vaccine targets five major serogroups of&nbsp;Neisseria meningitidis&nbsp;(A, B, C, W, and Y), which commonly cause invasive meningococcal disease (IMD).
The vaccine <a target="_blank" href="https://www.gsk.com/en-gb/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/" rel="noreferrer noopener">combines</a> the antigenic components of GSK&#8217;s two well-established meningococcal vaccines,&nbsp;Bexsero&nbsp;(Meningococcal Group B&nbsp;Vaccine) and&nbsp;Menveo&nbsp;(Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197&nbsp;Conjugate Vaccine).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43492835/gsk-launches-share-buyback-of-around-25-billion-after-better-than-expected-q4-earnings-raises-long-term-annual-sales-forecast-to-over-50-billion" rel="noreferrer noopener">GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion</a>
The regulatory&nbsp;application&nbsp;was supported by results from two phase 3 trials, which evaluated the vaccine&#8217;s safety, tolerability, and immune response in over 4,800 participants aged 10-25.&nbsp;
The safety data demonstrated that the vaccine has a safety profile consistent with GSK&#8217;s licensed meningococcal vaccines.
Integrating GSK&#8217;s MenABCWY vaccine into healthcare provider practices could simplify meningococcal vaccination delivery and help protect more U.S. adolescents against the five common disease-causing serogroups—A, B, C, W, and Y—for which the US Centers for Disease Control and Prevention (CDC) have issued recommendations.
Although MenB is the leading cause of IMD among this population, less than 13% receive the recommended two-dose vaccination series; around 32% receive at least one dose. GSK manufactures three of every four MenB doses currently administered in the U.S., positioning the company well to lead in the U.S. market as MenB-containing vaccinations must be completed with the same manufacturer&#8217;s MenB vaccine.
At its meeting on February 26, 2025, the CDC&#8217;s Advisory Committee on Immunization Practices (ACIP) is expected to vote on recommendations for the appropriate use of GSK&#8217;s MenABCWY vaccine in adolescents and young adults.
Price Action: GSK stock is up 0.64% at $36.41 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43743230/rokus-growth-surges-analysts-raise-price-targets-as-company-expands-ad-reach" target="_blank" rel="noreferrer noopener">Roku&#8217;s Growth Surges: Analysts Raise Price Targets As Company Expands Ad Reach</a></li>
</ul>
Photo by HJBC via Shutterstock

FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week (UPDATED)

<a href="https://www.benzinga.com/topic/ken-griffin">Ken Griffin</a>'s <a href="https://www.benzinga.com/topic/citadel-securities">hedge fund Citadel</a> has placed a £305 million ($390 million) short bet against GSK PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), marking the largest wager against the UK pharma giant in over a decade, <a href="https://www.ft.com/content/6520c6eb-4a30-4909-9c86-1b6b2e471743">reported</a> the Financial Times. 
The position, disclosed to the UK's Financial Conduct Authority, amounts to 0.51% of GSK's outstanding shares.
<h2 class="wp-block-heading">GSK's Rally Faces A Reality Check</h2>
GSK stock has climbed 8.20% in the past month, fueled by a £2 billion ($2.5 billion approx.) stock buyback and strong HIV and cancer drug sales. Yet, it still trails peers. 
Over the past five years, GSK shares have declined 17.53%, while the S&amp;P 500 pharmaceutical index has surged 45%. Griffin's short signals skepticism over the company's long-term pipeline, especially as its HIV drugs near a patent cliff.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/02/43638136/goldman-sachs-turns-bearish-on-vaccine-maker-dynavax-amid-shingles-and-hepatitis-b-uncertainty">Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty</a>
<h2 class="wp-block-heading">Hedge Funds, Analysts Are Split</h2>
This isn't the first time hedge funds have circled GSK. In 2021, activist investor Elliott Management pushed for a leadership shake-up. 
Meanwhile, JPMorgan analysts view GSK's latest earnings and guidance as "positive," but question the buyback's timing. Barclays called it "unexpected," while Jefferies deemed it "well received."
<h2 class="wp-block-heading">Takeaways For Investors</h2>
GSK's challenges have led to mixed bets on its future, but investors seeking exposure to Big Pharma without GSK's risks may look at industry leaders like Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). 
Alternatively, the iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) and SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>) provide diversified exposure.
With Citadel betting against GSK, the stock could see increased volatility—making it one to watch.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43598644/deadly-bird-flu-strain-detected-in-nevada-man-4-stocks-to-watch">Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch</a></li>
</ul>
Image: Shutterstock

Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors

<a href="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm" title="https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm">https://www.cdc.gov/mmwr/volumes/74/wr/mm7404a2.htm</a>

U.S. CDC Report: Evidence Found Of Recent Bird Flu Infections Among 3 Cattle Veterinarians

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for&nbsp;APRETUDE (cabotegravir tablets and extended release injectable suspension) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative.1
ViiV Healthcare is committed to ensuring timely public access for APRETUDE to help reduce the risk of sexually acquired HIV-1 infection and make progress towards global targets of ending HIV by 2030, which Canada endorsed.2,3&nbsp;ViiV Healthcare recognizes the pCPA's efforts and shared commitment to achieving this goal. This milestone underscores the need to expedite public reimbursement and as such, ViiV Healthcare looks forward to working with provincial and territorial governments and other stakeholders to make APRETUDE available through public drug plans.
APRETUDE is the first and only long-acting injectable approved in Canada and is indicated for at-risk adults and adolescents aged 12 years and older and weighing at least 35 kg for PrEP to reduce the risk of sexually acquired HIV-1 infection. APRETUDE for PrEP has demonstrated superior efficacy to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF tablets) in reducing the risk of HIV acquisition in two clinical trials, giving Canadians more options for PrEP.1&nbsp;

ViiV Healthcare And The Pan-Canadian Pharmaceutical Alliance Finalize Negotiations For APRETUDE For HIV-1 Pre-Exposure Prophylaxis

Editor's Note: This article has been updated to reflect that GSK acquired full rights to CureVac&#8217;s bird flu vaccine candidate.
A Nevada dairy worker has screened positive for the D1.1 strain of bird flu associated with a Louisiana man's death in January, according to a CNN <a href="https://www.cnn.com/2025/02/08/health/bird-flu-variant-nevada-human-case/index.html">report</a>. The Centers for Disease Control and Prevention is working Monday to confirm<a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says"> the initial positive test.</a>
The Details: The Nevada dairy worker who has initially tested positive is currently experiencing mild symptoms, including conjunctivitis or "pink eye," which appears to be a common symptom in recent human infections.&nbsp;
Last week, the U.S. Department of Agriculture said six dairy herds in Nevada<a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says"> tested positive</a> for the D1.1 strain of bird flu, marking the first time the variant of the H5N1 virus was detected in cattle.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a>
The<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html"> current public health</a> risk remains low, according to the CDC. The agency is using flu surveillance systems to monitor for H5 bird flu activity in people.&nbsp;
In January, President Donald Trump <a href="https://www.benzinga.com/general/health-care/25/01/43194764/trump-administration-halts-all-communications-from-the-centers-for-disease-control-as-bird-flu-spreads">ordered </a>a stop to all communications from CDC. Its website currently displays a banner stating that the site is being "modified to comply with President Trump's Executive Orders."
The CDC resumed publishing its weekly <a href="https://www.cdc.gov/mmwr/index2025.html?ACSTrackingID=USCDC_921-DM144964&amp;ACSTrackingLabel=This%20Week%20in%20MMWR:%20Vol.%2074,%20February%206,%202025&amp;deliveryName=USCDC_921-DM144964">scientific report</a>, the Morbidity and Mortality Weekly Report, last Thursday after being paused for the previous two weeks.&nbsp;
What Else: The H5N1 avian flu continues to spread in wild bird populations as well as in domestic flocks. As many as 15 birds at the Queens and Bronx zoos died last week as a result of the bird flu and a zoo spokesperson<a href="https://gothamist.com/news/bird-flu-suspected-in-deaths-across-multiple-species-at-queens-and-bronx-zoos"> told</a> Gothamist that "vulnerable bird species&#8221; have been moved to protected areas as vets work with city, state and federal regulators.&nbsp;
New York Governor Kathy Hochul has ordered live poultry markets in New York City, Westchester and Long Island to close after several bird flu cases were detected in Queens, Brooklyn and the Bronx last week.&nbsp;
According to the National Emerging Special Pathogens Training &amp; Education Center, more than 60 million poultry have died or<a href="https://netec.org/2023/01/30/situation-report-highly-pathogenic-avian-influenza-ah5n1/"> been culled</a> due to bird flu since the outbreak began in 2022. More than 20 million egg-laying chickens were culled in the last quarter of 2024 alone, creating a large impact on the U.S. poultry industry.&nbsp;
Stocks To Watch: With another human case of bird flu likely having been detected, investors may want to monitor the following stocks that are connected with bird flu vaccines.
Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) in January received an additional $590 million award from the U.S. Department of Health and Human Services to accelerate the development of its mRNA-based influenza vaccines, including bird flu.
GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), which acquired full rights to the bird flu vaccine candidate from CureVac BV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) in July 2024, has initiated a Phase I/II study on its development. Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) also has bird flu vaccine candidates in clinical trials.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details">Ford Shares Skid After Q4 Report: Details</a></li>
</ul>
Image: Shutterstock

Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch (CORRECTED)

Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reflecting updated views and recent competitive <a target="_blank" href="https://www.benzinga.com/quote/DVAX" rel="noreferrer noopener">dynamics for vaccines</a>.
Goldman Sachs analyst Paul Choi has downgraded Dynavax to Sell from Neutral and cut the <a target="_blank" href="https://www.benzinga.com/quote/DVAX/analyst-ratings" rel="noreferrer noopener">price target from $15 to $12</a>. He notes growing competition in the shingles vaccine market, which could reduce the potential value of the Z-1018 program and add uncertainty to its long-term revenue.
Potential convenience improvements come from GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Shingrix with the company's pre-filled syringes, which have been accepted for review by <a target="_blank" href="https://www.benzinga.com/25/02/43492835/gsk-launches-share-buyback-of-around-25-billion-after-better-than-expected-q4-earnings-raises-long-term-annual-sales-forecast-to-over-50-billion" rel="noreferrer noopener">both the FDA and EMA</a> (U.S. decision expected by 20 June).
Dynavax is conducting a Phase 1/2 trial to evaluate the safety, tolerability, and immunogenicity of Z-1018 compared to GSK's Shingrix in 441 healthy adults aged 50 to 69.
Choi also points to uncertain demand for repeat hepatitis B vaccinations in the 2030s, which may impact Heplisav-B's outlook beyond its peak sales. Despite its market share gains, questions remain about the FDA and ACIP's regulatory stance on vaccines in the U.S.
Last month,&nbsp;Dynavax announced preliminary HEPLISAV-B net product revenue of&nbsp;$268 million&nbsp;for 2024, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42945098/dynavax-announces-preliminary-unaudited-fourth-quarter-and-full-year-2024-financial-highlights" rel="noreferrer noopener">up 26% year-over-year</a>.
HEPLISAV-B net product revenue reached&nbsp;$71 million&nbsp;for the fourth quarter of 2024, up 39%.
In May 2024, the FDA issued a Complete Response Letter stating that the application did not provide sufficient data to fully evaluate the effectiveness or safety of a four-dose <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38818397/fda-declines-to-approve-expanded-use-of-dynavaxs-hepatitis-b-vaccine-in-hemodialysis-patients" rel="noreferrer noopener">regimen of HEPLISAV-B</a>.&nbsp;
Dynavax is expected to report fourth-quarter earnings <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43548293/dynavax-to-report-fourth-quarter-and-full-year-2024-financial-results-and-host-conference-call-on-" rel="noreferrer noopener">on 20 February</a>.
As per data from Benzinga Pro, analysts estimate Q4 adjusted EPS of $0.04, with sales of $72.92 million.
Analysts forecast 2024 sales of $278.13 million and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">adjusted EPS of $0.12</a>.
Price Action: DVAX stock is down 4.13% at $12.66 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43629227/nano-cap-lipella-pharmaceuticals-stock-jumps-on-positive-trial-data-in-patients-with-sore-mouth-membranes" target="_blank" rel="noreferrer noopener">Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes</a></li>
</ul>

Analyst Color

Downgrades

Price Target

Analyst Ratings

Movers

DVAX

Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty

U.S. stocks were mostly lower, with the Nasdaq Composite falling around 100 points on Wednesday.
Shares of Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter EPS results. B of A Securities raised its price target on the stock <a href="https://www.benzinga.com/25/02/43492624/electronic-arts-sees-strong-q3-earnings-boosted-by-ea-sports-fc-success-25-billion-shareholder-return-plan">from $130 to $132</a>.
Electronic Arts posted net bookings of $2.215 billion and GAAP earnings of $1.11 per share, beating estimates of $1.07 per share.
Electronic Arts shares jumped 5.4% to $127.83 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>BigBear.ai Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) shares surged 33.99% to $6.58. BigBear.ai won Department of Defense contract to prototype near-peer adversary geopolitical risk analysis for Chief Digital and Artificial Intelligence Office.</li>
<li>Criteo SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) shares jumped 20% to $46.06 following better-than-expected fourth-quarter reported financial results and an increase in its share buyback authorization program.</li>
<li>Mercury Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) gained 19% to $49.68 after the company reported better-than-expected quarterly financial results.</li>
<li>Tilray Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) gained 17% to $1.16.</li>
<li>SSR Mining Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSRM#NASDAQ">SSRM</a>) gained 16.8% to $9.57 after RBC Capital upgraded the stock from Underperform to Sector Perform and raised its price target from $5.5 to $8.</li>
<li>Mattel Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) rose 12.7% to $20.37 following better-than-expected fourth-quarter financial results. Jefferies upgraded the stock from Hold to Buy following the report.</li>
<li>Embraer SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERJ#NYSE">ERJ</a>) gained 11.6% to $44.48 after its executive jets subsidiary announced a purchase agreement with Flexjet in which it secured a $7 billion order.</li>
<li>Johnson Controls International PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) gained 11.2% to $85.97 after the company reported better-than-expected first-quarter financial results and FY25 outlook. They also appointed Joakim Weidemanis as next CEO.</li>
<li>Mueller Water Products Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWA#NYSE">MWA</a>) gained 10.8% to $25.60 following better-than-expected quarterly reported financial results. Additionally, the company raised its FY25 adjusted EBITDA guidance and issued FY25 revenue guidance above estimates.</li>
<li>Champion Homes Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKY#NYSE">SKY</a>) gained 9.5% to $101.61 after the company reported better-than-expected quarterly financial results.</li>
<li>Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) rose 8.7% to $67.21 after TD Cowen reinstated a Buy rating on the stock and announced a price target of $74.</li>
<li>Bloom Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) gained 8.2% to $25.02.</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) gained 7.8% to $37.52 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Fiserv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) shares surged 7.1% to $229.37 following better-than-expected quarterly reported financial results.</li>
<li>Powell Industries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) gained 5.8% to $246.82. Powell Industries raised its quarterly dividend to $0.2675 per share.</li>
<li>BioNTech SE – ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) rose 5.7% to $123.76.</li>
<li>Toyota Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) gained 3.8% to $194.68 after the company reported a year-over-year increase in third-quarter financial results and issued FY25 guidance above estimates.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Intraday Update

BBAI

BNTX

CRTO

Embraer-Empresa Brasileira De Aeronautica

MRCY

POWL

SSRM

TLRY

Electronic Arts Posts Upbeat Earnings, Joins Mattel, Johnson Controls, Mueller Water Products And Other Big Stocks Moving Higher On Wednesday

Wednesday,&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)&nbsp;reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The analysts&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimated sales of $9.58 billion</a>.
Vaccine sales fell 14% (-11% at constant currency) to 2.21 billion pounds, primarily impacted by lower demand for Arexvy related to a more limited ACIP recommendation in the U.S. and channel inventory consumption compared to launch year stocking in 2023. Arexvy sales reached 158 <a target="_blank" href="https://www.benzinga.com/25/01/42873977/safety-labels-updated-for-pfizer-and-gsks-rsv-vaccines-fda-adds-warning-for-rare-neurological-disorder" rel="noreferrer noopener">million pounds, down 70%</a>.
Meningitis vaccines had their strongest year of sales to date, with double-digit growth across all regions of 295 million. Established vaccine sales of 806 million, growing internationally and in the U.S.
Vaccines performance was also adversely <a target="_blank" href="https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2024-performance-with-further-improvement-to-long-term-growth-outlook/" rel="noreferrer noopener">impacted</a> due to COVID-19 solution sales and U.S. CDC stockpile replenishments in 2023, each impacting full year growth by 1 percentage point.
Shingrix sales reached 848 million pounds, down 7% (-4% at constant currency).
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43257413/trumps-executive-order-leads-to-cdc-halting-collaboration-with-who-amid-h5n9-bird-flu-discovery-and-rfk-jrs-senate-hearings" rel="noreferrer noopener">Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?</a>
Specialty Medicine sales increased 14% to 3.29 billion pounds. HIV drug revenues increased by 11% to&nbsp;1.97 billion pounds. General Medicines sales rose by 1% to&nbsp;2.61 billion pounds.
Trelegy (asthma drug) sales reached 669 million pounds, up 14%.
The company reported core EPS of $0.59 (23.2 pence), down 10%&nbsp;in&nbsp;constant currency and 20% on a reported basis, beating the consensus of $0.43.
Stock Buyback: GSK also said it would buy back 2 billion pounds of shares over the next 18 months.
Guidance:&nbsp;GSK expects 2025 sales to grow between 3% and 5%, with core earnings per share growing between 6% and 8%, including the benefit from the share buyback.
Specialty Medicines sales are expected to increase by a low double-digit percent, Vaccine turnover is expected to decrease by a low single-digit percent, and General Medicines are expected to be broadly stable.
The pharma giant boosted its long-term growth outlook and now expects over 40 billion pounds of sales in 2031, <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43010436/gsk-highlights-new-approvals-vaccine-momentum-at-jp-morgan-healthcare-conference" rel="noreferrer noopener">up from 38 billion pounds</a>.
The increase reflects the inclusion of Blenrep, the significant phase 3 progress since last year and multiple launch opportunities in the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41986367/gsk-raises-prospects-for-withdrawn-blood-cancer-drug-blenrep-to-return-to-us-market-heres-why" rel="noreferrer noopener">2025 to 2031 period</a>.
Price Action:&nbsp;At last check on Wednesday, GSK stock was up 6.20% ro $37.01 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43488899/your-oreos-to-cost-more-mondelez-warns-of-unprecedented-cocoa-price" target="_blank" rel="noreferrer noopener">Snacks Giant Mondelez Q4 Earnings: Sales Miss, EPS Falls Short, Cocoa Inflation Threatens 2025 &amp; More</a></li>
</ul>
Photo by HJBC via Shutterstock

Earnings

Guidance

Buybacks

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion

WIIM

GSK shares are trading higher after the company reported better-than-expected Q4 financial results.

ALGN

AMSC

AOSL

APPS

ARAY

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

2025 Guidance&nbsp;
GSK provides its full-year guidance at constant exchange rates (CER).&nbsp;
<ul>
<li>Turnover is expected to increase between 3 to 5 per cent&nbsp;</li>
<li>Core operating profit is expected to increase between 6 to 8 per cent&nbsp;</li>
<li>Core earnings per share is expected to increase between 6 to 8 per cent&nbsp;</li>
</ul>
This guidance is supported by the following turnover expectations for full-year 2025 at CER&nbsp;
<ul>
<li>Specialty Medicines – expected increase of a low double-digit per cent in turnover&nbsp;</li>
<li>Vaccines – expected decrease of a low single-digit per cent in turnover&nbsp;</li>
<li>General Medicines – expected to be broadly stable for turnover</li>
</ul>

GSK Expects 2025 Turnover Growth Of 3%-5%, Core EPS Rise Of 6%-8%, And Core Operating Profit Growth Of 6%-8%

GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.43 by 38.37 percent. This is a 17.13 percent decrease over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $10.404 billion which beat the analyst consensus estimate of $9.579 billion by 8.61 percent. This is a 3.37 percent increase over sales of $10.065 billion the same period last year.

Earnings Beats

GSK Q4 2024 Adj. EPS $0.59 Beats $0.43 Estimate, Sales $10.404B Beat $9.579B Estimate

Trump Health Sec Nominee Kennedy Says He Will Support Development Of Vaccines For Bird Flu

<a href="https://www.youtube.com/watch?v=e040JFe7bK0">https://www.youtube.com/watch?v=e040JFe7bK0</a>
&nbsp;

Trump Health Sec Nominee Kennedy Says He Will Not Pause Research On Bird Flu; Says He Will "Devote The Appropriate Resources To Preventing Pandemics" With Respect To Bird Flu

The submitted indications are for add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype who are inadequately controlled on medium to high dose corticosteroids (ICS) plus another asthma controller and also as an add-on treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
 &nbsp;

The European Medicines Agency Has Accepted For Review GSK's Marketing Authorization Application For The Use Of Depemokimab In Two Indications

Global health concerns escalated Monday as the U.S. Centers for Disease Control and Prevention reportedly halted collaboration with the World Health Organization, coinciding with the discovery of a rare H5N9 bird flu strain in California and upcoming Senate confirmation hearings for vaccine skeptic Robert F. Kennedy Jr.
What Happened: The developments sent ripples through healthcare stocks, with vaccine manufacturers showing mixed reactions. Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) edged up 0.58%, while Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) gained 2.95% amid heightened focus on potential bird flu preparedness.
CDC official John Nkengasong&#8216;s Sunday memo, <a href="https://apnews.com/article/cdc-who-trump-548cf18b1c409c7d22e17311ccdfe1f6">viewed</a> by The Associated Press, ordered an immediate stop to all WHO collaborations, catching health experts off guard as the U.S. faces multiple health challenges, including 13 measles outbreaks this year.
The first U.S. H5N9 outbreak, detected at a Merced County duck farm alongside the more common H5N1 strain, led to the culling of 119,000 birds, Reuters reported.
The discovery comes as egg prices nationwide hit $4.15 per dozen in December. The United States Department of Agriculture is projecting a further 20% increase this year due to ongoing bird flu impacts, according to a separate Associated Press <a href="https://apnews.com/article/egg-prices-bird-flu-poultry-inflation-9ea9934e20e3fe393abb1bb85aa31c30">report</a>.
The timing is particularly significant as Kennedy, known for his vaccine skepticism, faces Senate confirmation hearings this week for Health and Human Services Secretary. His potential appointment has already influenced market sentiment, with some vaccine stocks experiencing volatility.
&#8220;The concurrent WHO separation and emerging health threats create significant uncertainty for healthcare investors,&#8221; said Dr. Jeffrey Klausner, a University of Southern California public health expert.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43256425/nvidia-says-deepseek-an-illustration-of-how-new-ai-models-can-be-created-while-being-export-control-compliant-amid-600-billion-market-value-plunge">Nvidia Says DeepSeek An &#8216;Illustration&#8217; Of How New AI Models Can Be Created While Being Export-Control Compliant Amid $600 Billion Market Value Plunge</a>
Why It Matters: The healthcare sector&#8217;s response reflects broader market concerns. The iShares Genomics Immunology and Healthcare ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NASDAQ">IDNA</a>) has gained 1.2% year-to-date, while <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">major vaccine producers</a> maintain substantial government contracts for flu preparedness.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), GlaxoSmithKline PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), and other manufacturers secured $72 million in federal funding last October for bird flu vaccine production. Moderna separately received $176 million from BARDA for mRNA-based H5N1 vaccine development.
The CDC decision follows President Donald Trump&#8216;s executive order to withdraw from WHO, though the complete withdrawal requires congressional <a href="https://www.benzinga.com/25/01/43125408/trump-signs-order-to-withdraw-us-from-who-again-cites-funding-governance-concerns">approval and a one-year notice period</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43256454/bitcoin-ethereum-dogecoin-recover-as-deepseek-troubles-mount-for-us-tech-stocks-analyst-suggests-btc-could-hit-fresh-highs-over-upcoming-two-weeks">Bitcoin, Ethereum, Dogecoin Recover As DeepSeek Troubles Mount For US Tech Stocks: Analyst Suggests BTC Could Hit Fresh Highs Over Upcoming Two Weeks</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?

GSK shares are trading higher after the company announced the European Medicines Agency will review Shingrix for regulatory application.

The European Medicines Agency Has Accepted For Review The Regulatory Application Of A Prefilled Syringe Presentation Of Shingrix, GSK's Recombinant Zoster Vaccine

As the bird flu virus continues to spread through the United States among poultry, dairy cows and several recent human cases among poultry workers, on Tuesday the Trump administration ordered all communications from the Centers for Disease Control <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">and Prevention to stop</a>.&nbsp;
The Details: Acting Secretary of the U.S. Department of Health and Human Services Dorothy Fink followed by halting all reports from health agencies like the CDC, Food and Drug Administration and the National Institutes of Health on Tuesday, according to <a href="https://www.washingtonpost.com/health/2025/01/22/trump-health-communications-cdc-hhs-fda/56777086-d8e4-11ef-85a9-331436ec61e9_story.html">a report</a> from the Washington Post.&nbsp;
In a memo obtained by the Associated Press, Fink communicated that an "immediate pause" was ordered on regulations, guidance, announcements, press releases, social media posts and website posts through at least Feb. 1.&nbsp;
Read Next: <a href="https://www.benzinga.com/etfs/emerging-market-etfs/25/01/43130930/trump-looking-at-10-tariff-on-china-starting-feb-1">Trump &#8216;Looking At&#8217; 10% Tariff On China Starting Feb. 1&nbsp;</a>
The pause also includes the CDC's Morbidity and Mortality Weekly Report, a Centers for Disease Control and Prevention scientific publication on health information and recommendations.
Some medical experts are concerned that the lack of communication from key health agencies could put public health in jeopardy.&nbsp;
"Not a day goes by when CDC isn't tracking a potential threat to our health," Richard Besser, MD, former acting director of the CDC, told CNN.
"Right now they are letting us know about bird flu in cows, birds, and people … Cutting off communications from CDC puts our health at risk and prevents our doctors, nurses, and public health leaders in our communities from doing their jobs. I urge the administration to quickly lift the pause," Besser continued.
Bird Flu Update: The H5 bird flu is widespread in wild birds and is causing outbreaks in poultry and U.S. dairy cows with several recent human cases in U.S. dairy and poultry workers.
There have been 67 confirmed human cases of bird flu in the U.S. since 2024, including one death. The CDC<a href="https://www.cdc.gov/bird-flu/situation-summary/index.html"> says it is</a> &#8220;watching the situation carefully and working with states to monitor people with animal exposures.&#8221;
The New York Times<a href="https://www.nytimes.com/2025/01/23/nyregion/long-island-duck-farm-bird-flu.html"> reported</a> on Thursday that an outbreak of H5NI avian flu hit the last remaining duck farm on Long Island and all 100,000 ducks on the farm must be killed.&nbsp;
Before President Donald Trump took office last week, the CDC issued a new <a href="https://www.benzinga.com/general/biotech/25/01/43046294/bird-flu-raising-red-flags-among-health-officials-cdc-urges-faster-testing">health advisory</a> recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu <a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">virus within 24 hours.&nbsp;</a>
Vaccines: Last Friday Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) announced<a href="https://www.benzinga.com/general/biotech/25/01/43117087/bird-flu-update-first-commercial-case-in-georgia-moderna-receives-590-million-to-develop-vaccine"> it received</a> an additional $590 million award from the HHS to accelerate the development of its mRNA-based influenza vaccines, including bird flu.
Other pharmaceutical companies, including Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), have bird flu vaccine candidates currently in clinical trials and CureVac NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) started a phase I/II study on its bird flu vaccine candidate developed in collaboration with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>).&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a></li>
</ul>
Photo via Shutterstock.

Government

Politics

Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads

Legal

Press Releases

Shareholders that lost money on GSK plc(GSK) should contact Levi & Korsinsky about pending Class Action - GSK

GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit

GSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Contact The Gross Law Firm by April 7, 2025 Deadline to Join Class Action Against GSK plc(GSK)

DEADLINE ALERT for TIXT, MODV, GSK, MPWR: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

DEADLINE ALERT for MPWR, GSK, and ICLR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Gross Law Firm Notifies GSK plc Investors of a Class Action Lawsuit and Upcoming Deadline – GSK

GSK plc Class Action: Levi & Korsinsky Reminds GSK Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - GSK

Deadline Alert: GSK plc. (GSK) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

April 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against GSK

ICLR

MODV

MPWR

TIXT

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Goldman Sachs

Morgan Stanley

<a href="https://www.benzinga.com/topic/ken-griffin" target="_blank" rel="noopener">켄 그리핀</a>의 <a href="https://www.benzinga.com/topic/citadel-securities" target="_blank" rel="noopener">헤지펀드 시타델(Citadel)</a>이 GSK PLC(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)에 3억 5,000만 파운드(3억 9,000만 달러)의 공매도 베팅을 걸었다. 이는 영국 제약 대기업 GSK에 대한 10년래 가장 큰 베팅이라고 파이낸셜타임스가 <a href="https://www.ft.com/content/6520c6eb-4a30-4909-9c86-1b6b2e471743" target="_blank" rel="noopener">보도했다</a>.
영국 금융감독청(Financial Conduct Authority)이 공개한 이 포지션은 GSK 발행 주식의 0.51%에 해당한다.
<h3>GSK의 랠리, 현실 검증에 직면</h3>
GSK 주가는 지난 한 달 동안 20억 파운드(약 25억 달러)의 자사주 매입과 HIV 및 암 치료제 판매 호조에 힘입어 8.20% 상승했다. 하지만 여전히 동종 업계에 뒤처져 있다.
지난 5년 동안 GSK 주가는 17.53% 하락한 반면 S&amp;P 500 제약 지수는 45% 급등했다. 시타델의 공매도는 특히 HIV 약물이 특허 절벽에 가까워지면서 GSK의 장기적인 파이프라인에 대한 회의적인 신호를 보낸다.
<h3>헤지펀드, 애널리스트들의 의견 엇갈려</h3>
헤지펀드가 GSK를 두고 움직인 것은 이번이 처음은 아니다. 2021년에는 행동주의 투자자 엘리엇 매니지먼트가 경영진 교체를 추진했다.
한편 JP모건 애널리스트들은 GSK의 최근 실적과 가이던스를 "긍정적"으로 보고 있지만 자사주매입 시점에 대해서는 의문을 제기하고 있다. 바클레이즈는 "예상치 못한 일"이라고 말했고, 제프리스는 "잘한 일"이라고 평가했다.
<h3>투자자를 위한 시사점</h3>
시타델의 GSK 베팅으로 인해 주가 변동성이 커질 수 있음으로 주목해야 할 것이다.
GSK의 도전 과제는 엇갈린 베팅으로 이어졌지만, GSK의 위험 없이 대형 제약사에 노출되기를 원하는 투자자는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)와 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) 같은 제약업계 선두 주식에 주목할 수 있다.
대안으로는 iShares U.S. Pharmaceuticals ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)와 SPDR S&amp;P Pharmaceuticals ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)를 통해 분산된 노출을 제공받을 수 있다.
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

네바다의 한 낙농업자가 1월에 루이지애나 남자의 사망과 관련된 조류 독감 D1.1 변종에 양성 반응을 보였다고 CNN이 <a href="https://www.cnn.com/2025/02/08/health/bird-flu-variant-nevada-human-case/index.html">보도</a>했다. 미국 질병통제예방센터(CDC)는 월요일에 <a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says" target="_blank" rel="noopener" data-google-interstitial="false">초기 양성 반응</a>을 확인하기 위해 작업 중이다.
상세 내용: 초기 양성 반응을 보인 네바다의 낙농업자는 현재 결막염 또는 &#8220;핑크 아이&#8221;를 포함한 경미한 증상을 겪고 있으며, 이는 최근 인간 감염에서 흔히 나타나는 증상으로 보인다.
지난주 미국 농무부는 네바다주에 있는 6마리의 젖소가 <a href="https://www.benzinga.com/general/health-care/25/02/43549057/deadly-bird-flu-strain-hits-dairy-cows-could-make-covid-seem-like-a-walk-in-the-park-expert-says">조류 독감 D1.1 변종에 양성 반응</a>을 보였다고 밝혔다. 이는 H5N1 바이러스 변종이 소에서 처음으로 발견된 사례이다.
다음 읽기: <a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">팔란티어, 일론 머스크의 AI 챗봇 그록을 AIP에 추가하다</a>
CDC에 따르면 <a href="https://www.cdc.gov/bird-flu/situation-summary/index.html">현재 공공 보건</a> 위험은 낮다. 이 기관은 인플루엔자 감시 시스템을 사용하여 사람들에서 H5 조류 독감 활동을 모니터링하고 있다.
1월에 도널드 트럼프 대통령은 <a href="https://www.benzinga.com/general/health-care/25/01/43194764/trump-administration-halts-all-communications-from-the-centers-for-disease-control-as-bird-flu-spreads">CDC의 모든 커뮤니케이션을 중지하라고 명령</a>했다. 현재 CDC 웹사이트에는 &#8220;트럼프 대통령의 행정명령에 따라 수정 중이다&#8221;라는 배너가 표시되고 있다.
CDC는 지난 목요일에 2주 동안 중단되었던 주간 <a href="https://www.cdc.gov/mmwr/index2025.html?ACSTrackingID=USCDC_921-DM144964&amp;ACSTrackingLabel=This%20Week%20in%20MMWR:%20Vol.%2074,%20February%206,%202025&amp;deliveryName=USCDC_921-DM144964">과학 보고서</a>인 주간 질병 사망률 보고서를 다시 발표했다.
기타 사항: H5N1 조류 독감은 야생 조류와 가금류에서 계속 퍼지고 있다. 지난주에 퀸즈와 브롱크스 동물원에서 15마리의 조류가 조류 독감으로 사망했으며, 동물원 대변인은 &#8220;취약한 조류 종&#8221;이 보호 구역으로 옮겨졌다고 <a href="https://gothamist.com/news/bird-flu-suspected-in-deaths-across-multiple-species-at-queens-and-bronx-zoos">고다미스트(Gothamist)</a>에 밝혔다. 수의사들이 시, 주 및 연방 규제 기관과 협력하고 있다.
뉴욕 주지사 캐시 호컬은 퀸즈, 브루클린 및 브롱크스에서 조류 독감 사례가 발견된 후 뉴욕시, 웨스트체스터 및 롱아일랜드의 살아있는 가금류 시장을 폐쇄하라고 명령했다.
국가 신흥 특수 병원체 훈련 및 교육 센터에 따르면, 2022년 조류 독감 발생 이후 6천만 마리 이상의 가금류가 사망하거나 <a href="https://netec.org/2023/01/30/situation-report-highly-pathogenic-avian-influenza-ah5n1/">도살</a>되었습니다. 2024년 4분기에는 2천만 마리 이상의 산란용 닭이 도살되어 미국 가금류 산업에 큰 영향을 미쳤다.
주목할 주식: 또 다른 인간 조류 독감 사례가 발견된 것으로 보이면서, 투자자들은 조류 독감 백신과 관련된 다음 주식들을 주의 깊게 모니터링할 수 있다.
모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)는 1월에 미국 보건복지부로부터 mRNA 기반 인플루엔자 백신, 특히 조류 독감 백신 개발을 가속화하기 위해 추가로 5억 9천만 달러의 지원을 받았다.
GSK(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)는 2024년 7월에 큐어백 BV(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>)로부터 조류 독감 백신 후보에 대한 모든 권리를 인수하고 개발에 대한 1상/2상 연구를 시작했다. 노바백스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) 또한 임상 시험 중인 조류 독감 백신 후보가 있다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43512137/ford-shares-skid-after-q4-report-details">포드4분기 보고서 발표 후 주가 하락: 세부사항</a></li>
</ul>
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 질병통제예방센터(CDC)가 세계보건기구(WHO)와의 협력을 중단한 것으로 알려지면서 전 세계 보건 우려가 월요일 높아지는 가운데, 캘리포니아에서 희귀한 H5N9 조류 독감 변종이 발견되어 백신 회의론자 로버트 F. 케네디 주니어에 대한 상원 인준 청문회가 예정된 것과 동시에 이루어졌다.
무슨 일이 있었나: 이러한 사태는 의료 관련 주식에 파장을 일으켰고, 백신 제조사들은 혼재된 반응을 보였다. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)는 월요일 0.58% 상승했고, 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)는 조류 인플루엔자 대비 준비 가능성에 대한 관심이 높아지면서 2.95% 상승했다.
CDC의 존 응켄가송(John Nkengasong) 공식의 일요일 메모는 <a href="https://apnews.com/article/cdc-who-trump-548cf18b1c409c7d22e17311ccdfe1f6">AP 통신</a>에 보도된 바와 같이 WHO와의 모든 협력을 즉시 중단하라는 명령을 내렸으며, 이는 미국이 올해 13건의 홍역 발병을 포함한 여러 건강 문제에 직면한 상황에서 건강 전문가들을 놀라게 했다.
첫 번째 H5N9 발생은 머시드 카운티의 한 오리 농장에서 발견되었으며, 더 일반적인 H5N1 바이러스와 함께 발견되어 119,000마리의 조류가 도살되었다고 로이터가 보도했다.
이 발견은 전국적으로 계란 가격이 12개에 4.15달러로 치솟은 12월에 발생했다. 미국 농무부는 조류 인플루엔자 영향으로 올해 계란 가격이 추가로 20% 상승할 것으로 전망하고 있다고 별도의 AP 통신 <a href="https://apnews.com/article/egg-prices-bird-flu-poultry-inflation-9ea9934e20e3fe393abb1bb85aa31c30">보도</a>했다.
타이밍은 특히 중요하다. 백신 회의론자로 알려진 케네디는 이번 주 보건복지부 장관 인준 청문회를 앞두고 있다. 그의 잠재적 임명은 이미 시장 심리에 영향을 미쳤으며, 일부 백신 주식은 변동성을 보였다.
&#8220;동시에 WHO와의 분리와 새로운 건강 위협이 발생하는 것은 의료 투자자들에게 상당한 불확실성을 야기한다&#8221;고 제프리 클라우스너(Jeffrey Klausner) 박사, 남가주대학교 공공보건 전문가가 말했다.
참고: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%EB%94%A5%EC%8B%9C%ED%81%AC%EA%B0%80-%EC%88%98%EC%B6%9C-%ED%86%B5%EC%A0%9C%EB%A5%BC-%EC%A4%80%EC%88%98%ED%95%98%EB%A9%B4%EC%84%9C-%EC%83%88-ai-%EB%AA%A8%EB%8D%B8/" target="_blank" rel="noopener">엔비디아가 딥시크를 &#8216;사례&#8217;로 언급하며 새로운 AI 모델이 수출 통제 준수 하에 생성될 수 있음을 설명</a>
중요한 이유: 의료 부문의 반응은 더 넓은 시장 우려를 반영한다. iShares Genomics Immunology and Healthcare ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NASDAQ">IDNA</a>)는 올해 1.2% 상승한 반면, <a href="https://www.benzinga.com/general/biotech/25/01/42882233/bird-flu-sparks-vaccine-stock-surge-etfs-to-watch-as-h5n1-outbreak-intensifies">주요 백신 생산자들</a>는 여전히 독감 대비를 위해 정부 계약을 상당수 보유하고 있다.
사노피 SA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), 글락소스미스클라인 PLC(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) 그리고 다른 제조사들은 작년 10월 조류 인플루엔자 백신 생산을 위한 7,200만 달러의 연방 자금을 확보했다. 모더나는 mRNA 기반 H5N1 백신 개발을 위해 미국 보건부(HHS) 산하 질병예방대응본부(ASPR) 직속 생물의학첨단연구개발국(BARDA)로부터 1억 7,600만 달러를 별도로 받았다.
CDC의 결정은 도널드 트럼프 대통령의 WHO 탈퇴 명령에 따른 것이지만, 완전한 탈퇴는 의회의 <a href="https://www.benzinga.com/25/01/43125408/trump-signs-order-to-withdraw-us-from-who-again-cites-funding-governance-concerns">승인과 1년의 통지 기간</a>이 필요하다.

다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/crypto/bitcoin/%EB%B9%84%ED%8A%B8%EC%BD%94%EC%9D%B8-%EC%9D%B4%EB%8D%94%EB%A6%AC%EC%9B%80-%EB%B0%8F-%EB%8F%84%EC%A7%80%EC%BD%94%EC%9D%B8%EC%9D%B4-%EC%86%8C%ED%8F%AD-%ED%9A%8C%EB%B3%B5-%EB%94%A5%EC%8B%9C%ED%81%AC/" target="_blank" rel="noopener">비트코인, 이더리움, 도지코인, 딥시크 문제로 미국 기술주가 어려움을 겪는 동안 회복: 분석가는 BTC가 향후 2주 동안 새로운 최고가를 기록할 수 있다고 제안</a></li>
</ul>
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 AI 도구의 도움을 받아 부분적으로 작성되었으며, Benzinga 편집자에 의해 검토 및 게시되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">비폭력 마약 범죄자 석방</a>를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다.
<a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">AP 통신</a>에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">트럼프의 취임식 하루 전</a>이다.
마감일이 다가오면서, 이 앱의 운명은 소위 &#8216;틱톡을 위한 국민 입찰&#8217;에 달려 있다. 이는 &#8220;샤크 탱크&#8221;의 케빈 오리어리(Kevin O&#8217;Leary)와 억만장자 프랭크 매코트(Frank McCourt)의 지원을 받는다. 분명히 틱톡의 미국 자산은 여전히 ​​손에 넣을 수 있지만 가격표나 거래가 <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">며칠 안에</a> 현실적으로 완료될 수 있는지 여부에 대해서는 아직 언급이 없습니다.
<h2 class="wp-block-heading">파산 블록</h2>
조앤(Joann Inc.)은 12개월 이내에 두 번째 파산 계획을 수립하고 있다. 오하이오 기반의 이 패브릭 및 공예 소매업체는 약 800개 매점의 포트폴리오 구매자를 찾고 있다.
고든 브라더스 리테일 파트너스(Gordon Brothers Retail Partners)가 "스톡킹 호스(stalking horse)" 입찰자로 나타났지만, 조앤은 여전히 더 나은 제안을 기대하고 있다. 아마도 바늘귀를 통과시키는 법을 아는 사람에게서 말이다.
이전에 82세의 소매업체는 사모펀드 레너드 그린 앤 파트너스(Leonard Green &amp; Partners)의 관리 하에 있었으며, 2011년 16억 달러의 레버리지 인수로 인수되었다. 이 회사는 부채에 묶여 있었고 (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">보도에 따르면</a> 2020년 10월 31일 기준 장기 부채가 9억 2,100만 달러였음) <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">2021년에 상장</a>되었다.
조앤은 <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">2024년 3월</a>에 다시 비공개로 전환되었으며, 당시 10억 달러의 총 부채를 약 5억 달러 줄이는 데 성공했다.
지난해 자구 노력이 무색해진 조앤은 최근 소매업체들의 증가하는 피해 사례에 합류하고 있다: <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">몇 가지를 예로 들면</a> 파티 시티(Party City), 빅랏츠(Big Lots), LL 플로링(LL Flooring), 더바디샵(The Body Shop) 및 더 컨테이너 스토어(The Container Store) 등이 있다.
컬크랜드 앤 앨리스(Kirkland &amp; Ellis)가 법률 문제를 처리하고 있으며, 센터뷰 파트너스(Centerview Partners LLC)가 재무 자문을 제공한다. 알바레즈 앤 마살 북미(Alvarez &amp; Marsal North America, LLC)가 구조조정 과정을 감독하고 있다.
<h2 class="wp-block-heading">신규 블록</h2>
<ul>
<li>투자 회사 KKR &amp; 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)가 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)를 고용하여 필리핀 핀테크 회사 마야(Maya)의 지분 매각 경매를 운영하도록 했다고 로이터가 보도했다.</li>
<li>뉴욕에 본사를 둔 KKR은 마야의 20% 이상의 지분을 보유하고 있으며, 매각이 진행된다면 마야의 가치는 20억 달러를 초과할 수 있다고 한 소식통이 전했다.</li>
<li>듀폰(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>)은 <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">전자 사업 분리</a>를 추진하고 있다. 델라웨어 주 윌밍턴에 본사를 둔 이 회사는 거래가 11월 1일까지 완료될 것으로 예상하고 있다. 듀폰은 전략적 대안을 평가한 후 수자원 사업을 유지하기로 결정했다.</li>
<li>인제비티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>)는 성과 화학 산업 전문 분야를 매각하고 있으며, 사우스 캐롤라이나주 노스 찰스턴 부지의 일부를 매각할 계획다. 이 회사는 이익 현금 흐름을 개선하고 검토 과정을 연말까지 마무리할 것으로 기대하고 있다. 거래 여부는 <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">아직 미정</a>이다.</li>
<li>S&amp;W 시드 컴퍼니(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>)는 매물에 나와 있다. 이는 합병 또는 재자본화도 고려 중이며, 이는 더 큰 전략적 검토의 일환이다. 콜로라도주 롱몬트에 본사를 둔 이 회사는 호주 자회사를 이미 매각했다. 앨런 윌리츠(Alan Willits) 회장은 "우리는 주주 가치를 최적화하는 모든 이니셔티브를 지원하고 있으며, S&amp;W 시드가 향후 성공을 위해 최적의 위치에 있도록 보장하기 위해 잠재적 전략적 대안의 전체 범위를 고려할 것이다"라고 밝혔다.</li>
</ul>
참고: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">스타 비행 시험 중 폭발, 일론 머스크: ‘성공은 불확실하지만 오락은 보장된다!'</a>
<h2 class="wp-block-heading">블록 업데이트</h2>
<ul>
<li>로렌코 곤칼베스(Lourenco Goncalves)는 월요일 기자 회견에서 주목을 받았다. <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">블룸버그</a>에 따르면, 클리브랜드 클리프스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>)의 CEO는 일본을 "악당"이라고 부르며, 중국에 해로운 관행인 덤핑과 과잉 생산을 가르쳤다고 비난했다. 그의 발언은 클리브랜드 클리프스가 U.S. 스틸(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>)에 대한 새로운 입찰을 노리고 있는 가운데 나왔으며, 바이든이 일본제철(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>)의 <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$140억 인수 시도</a>를 차단하기로 결정한 후이다. 자신의 회사를 잠재적 구매자로 포지셔닝하면서 곤칼베스의 수사는 철강 산업의 긴장을 고조시켰다. 일본제철은 이제 트럼프에게 <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">거래 성사를 도와달라고 요청</a>하고 있다.</li>
<li>T-모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)은 비스타 미디어(Vistar Media)를 6억 달러에 인수할 것이다. 이 통신 회사는 이 거래가 광고 사업을 강화할 것으로 기대하고 있다고 로이터가 보도했다.</li>
</ul>
지난주 생명공학 및 제약 부문 거래가 잇따랐다. 다음은 벤징가의 보도 샘플이다:
<ul>
<li>바이오젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)은 세이지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)의 모든 미상환 주식을 <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">주당 7.22달러에 인수하겠다는</a> 비공식 제안을 제출했다. 골드만삭스 애널리스트인 살빈 리히터(Salveen Richter)는 이 제안이 출산 후 우울증(PPD) 치료제인 주르주배(Zurzuvae) 런칭의 재무적 성공을 고려할 때 전략적으로 타당하다고 믿고 있다.</li>
<li>GSK plc(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)는 <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">IDRx, Inc., 위장관 간질성 종양(GIST)을 위한 정밀 치료제에 초점을 맞춘 생명공학 회사</a>를 10억 달러에 인수하기로 합의했다. 이 거래는 특정 규제 승인 이정표 후 GSK가 추가로 1억 5천만 달러를 지불해야 할 수도 있다.</li>
<li>일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 스콜피온 테라퓨틱스(Scorpion Therapeutics)의 초기 단계 <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">암 치료 프로그램을 25억 달러에 인수</a>했다.</li>
<li>브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)와 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 마찬가지로, 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)는 <a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal">150억 달러 거래로</a> 신경정신적 포트폴리오를 강화하려고 합니다.</li>
<li>크라운 래버러토리즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>)는 레반스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>)의 모든 미상환 보통주를 주당 3.10달러에 인수하겠다고 제안했다.</li>
<li>셀러리어스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)는 디코이 테라퓨틱스(Decoy Therapeutics)와의 거래를 체결했다. 이 회사는 펩타이드 접합 치료제에 초점을 맞춘 초기 단계 생명공학 회사이다. 통합된 개체는 호흡기 질환과 위장관 종양학의 미충족 요구 사항을 목표로 할 것이다.</li>
<li>란테우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)는 <a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging">3억 5천만 달러에 라이프 몰레큘러 이미징을 인수하여</a> 방사선 치료제 분야에서의 입지를 강화했다.</li>
<li> </li>
</ul>
지난주 딜 디스패치의 에디션은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-td-%EC%9D%80%ED%96%89%EC%9D%B4-%EC%B0%B0%EC%8A%A4-%EC%8A%88%EC%99%91-%EC%A7%80%EB%B6%84%EC%9D%84-%ED%8C%90%EB%A7%A4%ED%95%A0%EA%B9%8C-%EC%95%84/" target="_blank" rel="noopener">여기를 클릭하세요</a><a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">.</a>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">엑센트릭한 억만장자, 전설적인 영화 제작자 하워드 휴즈의 전 마이애미 저택이 5천 550만 달러에 매물로 나왔습니다.</a></li>
</ul>
이미지는 Shutterstock의 사진을 사용하여 생성되었습니다.


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ABBV

BIIB

LNTH

NGVT

NPSCY

RVNC

딜 디스패치: 바이든이 틱톡 금지를 트럼프에게 넘기고, 또 다른 유명 소매업체 파산

Comments

GSK

뉴스

에 대한 최신 뉴스 GSK (NYSE:GSK) 주식

월요일, 2월 17, 2025

목요일, 2월 13, 2025

화요일, 1월 28, 2025

일요일, 1월 19, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌